Clinical Trial Update: Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib as first-line therapy for locally advanced/metastatic papillary renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: UNICANCER | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED